{"id":"https://openalex.org/W2013899237","doi":"https://doi.org/10.1089/088922201750251981","title":"A Phase III Study of Recombinant Human Interferon Gamma to Prevent Opportunistic Infections in Advanced HIV Disease","display_name":"A Phase III Study of Recombinant Human Interferon Gamma to Prevent Opportunistic Infections in Advanced HIV Disease","publication_year":2001,"publication_date":"2001-06-10","ids":{"openalex":"https://openalex.org/W2013899237","doi":"https://doi.org/10.1089/088922201750251981","mag":"2013899237","pmid":"https://pubmed.ncbi.nlm.nih.gov/11429120"},"language":"en","primary_location":{"id":"doi:10.1089/088922201750251981","doi":"https://doi.org/10.1089/088922201750251981","is_oa":false,"landing_page_url":"https://doi.org/10.1089/088922201750251981","pdf_url":null,"source":{"id":"https://openalex.org/S161282271","display_name":"AIDS Research and Human Retroviruses","issn_l":"0889-2229","issn":["0889-2229","1931-8405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS Research and Human Retroviruses","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110135501","display_name":"Lynn Riddell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I225661044","display_name":"Barts Health NHS Trust","ror":"https://ror.org/00b31g692","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I225661044"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lynn A. Riddell","raw_affiliation_strings":["Andrewes Unit, Barts and the London NHS Trust, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Andrewes Unit, Barts and the London NHS Trust, London, UK","institution_ids":["https://openalex.org/I225661044"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110304503","display_name":"A J Pinching","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I225661044","display_name":"Barts Health NHS Trust","ror":"https://ror.org/00b31g692","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I225661044"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Anthony J. Pinching","raw_affiliation_strings":["Department of Immunology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK","Barts Health NHS Trust"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Immunology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK","institution_ids":["https://openalex.org/I166337079"]},{"raw_affiliation_string":"Barts Health NHS Trust","institution_ids":["https://openalex.org/I225661044"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Susan Hill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I225661044","display_name":"Barts Health NHS Trust","ror":"https://ror.org/00b31g692","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I225661044"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Susan Hill","raw_affiliation_strings":["Andrewes Unit, Barts and the London NHS Trust, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Andrewes Unit, Barts and the London NHS Trust, London, UK","institution_ids":["https://openalex.org/I225661044"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012486076","display_name":"Tony Ng","orcid":"https://orcid.org/0000-0003-3894-5619","observed_orcids":["https://orcid.org/0000-0003-3894-5619"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Tony T. Ng","raw_affiliation_strings":["Department of Immunology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK","Cancer Cell Biology & Imaging"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Immunology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK","institution_ids":["https://openalex.org/I166337079"]},{"raw_affiliation_string":"Cancer Cell Biology & Imaging","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012451434","display_name":"Emilio Arbe","orcid":"https://orcid.org/0000-0003-4572-8145","observed_orcids":["https://orcid.org/0000-0003-4572-8145"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]},{"id":"https://openalex.org/I4210112752","display_name":"Boehringer Ingelheim (United Kingdom)","ror":"https://ror.org/01jnnpe14","country_code":"GB","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210112752"]}],"countries":["DE","GB"],"is_corresponding":false,"raw_author_name":"Emilio Arbe","raw_affiliation_strings":["Boehringer Ingelheim Ltd., Bracknell, Berkshire, UK","BOEHRINGER INGELHEIM LTD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Ltd., Bracknell, Berkshire, UK","institution_ids":["https://openalex.org/I4210112752"]},{"raw_affiliation_string":"BOEHRINGER INGELHEIM LTD","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023803089","display_name":"Gary P. Lapham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]},{"id":"https://openalex.org/I4210112752","display_name":"Boehringer Ingelheim (United Kingdom)","ror":"https://ror.org/01jnnpe14","country_code":"GB","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210112752"]}],"countries":["DE","GB"],"is_corresponding":false,"raw_author_name":"Gary P. Lapham","raw_affiliation_strings":["Boehringer Ingelheim Ltd., Bracknell, Berkshire, UK","BOEHRINGER INGELHEIM LTD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Ltd., Bracknell, Berkshire, UK","institution_ids":["https://openalex.org/I4210112752"]},{"raw_affiliation_string":"BOEHRINGER INGELHEIM LTD","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Stephen Ash","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210163491","display_name":"Ealing Hospital NHS Trust","ror":"https://ror.org/0380w8h49","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210163491"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Stephen Ash","raw_affiliation_strings":["Department of Infectious Diseases, Ealing Hospital NHS Trust, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Infectious Diseases, Ealing Hospital NHS Trust, London, UK","institution_ids":["https://openalex.org/I4210163491"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031161184","display_name":"Richard John Hillman","orcid":"https://orcid.org/0000-0002-1859-0761","observed_orcids":["https://orcid.org/0000-0002-1859-0761"]},"institutions":[{"id":"https://openalex.org/I225661044","display_name":"Barts Health NHS Trust","ror":"https://ror.org/00b31g692","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I225661044"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Richard Hillman","raw_affiliation_strings":["Graham Hayton Unit, Barts and the London NHS Trust, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graham Hayton Unit, Barts and the London NHS Trust, London, UK","institution_ids":["https://openalex.org/I225661044"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030467691","display_name":"S E Tchamouroff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800342113","display_name":"Royal Sussex County Hospital","ror":"https://ror.org/05fe2n505","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800342113","https://openalex.org/I4210151332"]},{"id":"https://openalex.org/I4210151332","display_name":"University Hospitals Sussex NHS Foundation Trust","ror":"https://ror.org/03wvsyq85","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210151332"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Stephen Tchamouroff","raw_affiliation_strings":["Claude Nicol Centre, Royal Sussex County Hospital, Brighton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Claude Nicol Centre, Royal Sussex County Hospital, Brighton, UK","institution_ids":["https://openalex.org/I2800342113","https://openalex.org/I4210151332"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083752740","display_name":"David W. Denning","orcid":"https://orcid.org/0000-0001-5626-2251","observed_orcids":["https://orcid.org/0000-0001-5626-2251","https://orcid.org/0000-0002-0955-0151"]},"institutions":[{"id":"https://openalex.org/I2801440235","display_name":"North Manchester General Hospital","ror":"https://ror.org/02xesw687","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801440235","https://openalex.org/I4210092852"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David W. Denning","raw_affiliation_strings":["Department of Infectious Diseases, North Manchester General Hospital, Manchester, UK","Division of Infection, Immunity & Respiratory Medicine (L5)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Infectious Diseases, North Manchester General Hospital, Manchester, UK","institution_ids":["https://openalex.org/I2801440235"]},{"raw_affiliation_string":"Division of Infection, Immunity & Respiratory Medicine (L5)","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078054016","display_name":"Jacqueline Parkin","orcid":"https://orcid.org/0000-0002-6449-0542","observed_orcids":["https://orcid.org/0000-0002-6449-0542"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jacqueline M. Parkin","raw_affiliation_strings":["Department of Immunology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Immunology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK","institution_ids":["https://openalex.org/I166337079"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.1,"has_fulltext":false,"cited_by_count":52,"citation_normalized_percentile":{"value":0.72309337,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"17","issue":"9","first_page":"789","last_page":"797"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.4162999987602234,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.4162999987602234,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12369","display_name":"Pneumocystis jirovecii pneumonia detection and treatment","score":0.14169999957084656,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.12300000339746475,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/recombinant-interferon-gamma","display_name":"recombinant interferon-gamma","score":0.9259999990463257},{"id":"https://openalex.org/keywords/opportunistic-infections","display_name":"opportunistic infections","score":0.8920000195503235},{"id":"https://openalex.org/keywords/cd4-count","display_name":"CD4 count","score":0.5540000200271606},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.9860000014305115},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.5320000052452087},{"id":"https://openalex.org/keywords/candidiasis","display_name":"candidiasis","score":0.7910000085830688},{"id":"https://openalex.org/keywords/herpes-simplex-virus","display_name":"herpes simplex virus","score":0.7580000162124634},{"id":"https://openalex.org/keywords/cytomegalovirus","display_name":"cytomegalovirus","score":0.9079999923706055},{"id":"https://openalex.org/keywords/overdispersion","display_name":"overdispersion","score":0.6859999895095825}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8686426877975464},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7513455748558044},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6675572991371155},{"id":"https://openalex.org/C2778616394","wikidata":"https://www.wikidata.org/wiki/Q474959","display_name":"myalgia","level":2,"score":0.6168416142463684},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.515321671962738},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5103961825370789},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.413464218378067},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.32625067234039307},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.31847232580184937},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000890","descriptor_name":"Anti-Infective Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000890","descriptor_name":"Anti-Infective Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003257","descriptor_name":"Consumer Product Safety","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007371","descriptor_name":"Interferon-gamma","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007371","descriptor_name":"Interferon-gamma","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017088","descriptor_name":"AIDS-Related Opportunistic Infections","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1089/088922201750251981","doi":"https://doi.org/10.1089/088922201750251981","is_oa":false,"landing_page_url":"https://doi.org/10.1089/088922201750251981","pdf_url":null,"source":{"id":"https://openalex.org/S161282271","display_name":"AIDS Research and Human Retroviruses","issn_l":"0889-2229","issn":["0889-2229","1931-8405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS Research and Human Retroviruses","raw_type":"journal-article"},{"id":"pmid:11429120","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11429120","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS research and human retroviruses","raw_type":"Clinical Trial"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/254ddb8c-4294-40a5-b7cb-cbcb3b09078d","doi":null,"is_oa":false,"landing_page_url":"https://research.manchester.ac.uk/en/publications/254ddb8c-4294-40a5-b7cb-cbcb3b09078d","pdf_url":null,"source":{"id":"https://openalex.org/S4306400662","display_name":"Research Explorer (The University of Manchester)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I28407311","host_organization_name":"University of Manchester","host_organization_lineage":["https://openalex.org/I28407311"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Riddell, L A, Pinching, A J, Hill, S, Ng, T T, Arbe, E, Lapham, G P, Ash, S, Hillman, R, Tchamouroff, S, Denning, D W & Parkin, J M 2001, 'A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease', AIDS research and human retroviruses, vol. 17, no. 9, pp. 789-797. https://doi.org/10.1089/088922201750251981","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:kclpure.kcl.ac.uk:publications/14455827-5969-42f9-8b6b-e6e5a7492e27","doi":null,"is_oa":false,"landing_page_url":"https://kclpure.kcl.ac.uk/portal/en/publications/14455827-5969-42f9-8b6b-e6e5a7492e27","pdf_url":null,"source":{"id":"https://openalex.org/S4306400216","display_name":"Research Portal (King's College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I183935753","host_organization_name":"King's College London","host_organization_lineage":["https://openalex.org/I183935753"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Riddell, L A, Pinching, A J, Hill, S, Ng, T T, Arbe, E, Lapham, G P, Ash, S, Hillman, R, Tchamouroff, S, Denning, D W & Parkin, J M 2001, 'A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease', Aids Research and Human Retroviruses, vol. 17, no. 9, pp. 789 - 797. https://doi.org/10.1089/088922201750251981","raw_type":"info:eu-repo/semantics/publishedVersion"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":41,"referenced_works":["https://openalex.org/W88790481","https://openalex.org/W299799878","https://openalex.org/W1033069450","https://openalex.org/W1899461891","https://openalex.org/W1970356423","https://openalex.org/W1971604280","https://openalex.org/W1976694550","https://openalex.org/W1979129905","https://openalex.org/W1991337645","https://openalex.org/W1995225418","https://openalex.org/W1998090225","https://openalex.org/W2005150291","https://openalex.org/W2018541015","https://openalex.org/W2020223264","https://openalex.org/W2024791349","https://openalex.org/W2027548834","https://openalex.org/W2037723969","https://openalex.org/W2038256546","https://openalex.org/W2040476677","https://openalex.org/W2047349250","https://openalex.org/W2055397536","https://openalex.org/W2063140237","https://openalex.org/W2065158430","https://openalex.org/W2068871282","https://openalex.org/W2077911026","https://openalex.org/W2085089692","https://openalex.org/W2086561959","https://openalex.org/W2089262366","https://openalex.org/W2106774411","https://openalex.org/W2111023076","https://openalex.org/W2116258000","https://openalex.org/W2141896182","https://openalex.org/W2157376708","https://openalex.org/W2326805633","https://openalex.org/W2333546620","https://openalex.org/W2334923455","https://openalex.org/W2400902860","https://openalex.org/W2520163263","https://openalex.org/W4238237268","https://openalex.org/W4313305965","https://openalex.org/W4313347866"],"related_works":["https://openalex.org/W2141896182","https://openalex.org/W2395968712","https://openalex.org/W4290361661","https://openalex.org/W2323129988","https://openalex.org/W9139524","https://openalex.org/W2411730384","https://openalex.org/W2290526514","https://openalex.org/W1990425795","https://openalex.org/W2006255713","https://openalex.org/W2116696460"],"abstract_inverted_index":{"The":[0,80,223],"efficacy":[1],"and":[2,99,136,163,193,213],"safety":[3,230],"of":[4,13,32,87,108,125,139,159,185,218,221,232],"recombinant":[5],"human":[6],"interferon":[7],"gamma":[8],"(rIFN-gamma)":[9],"in":[10,16,34,113,168,177],"the":[11,85,114,132,137,144,157,169,178,207,229],"reduction":[12],"opportunistic":[14,211],"disease":[15],"patients":[17,36,48],"with":[18,37,120],"advanced":[19],"HIV-1":[20],"infection":[21],"are":[22],"assessed.":[23],"A":[24],"12-month":[25],"double-blind,":[26],"placebo-controlled,":[27],"multicenter,":[28],"Phase":[29],"III":[30],"trial":[31],"rIFN-gamma":[33,57,62,121,149,170],"HIV-positive":[35],"CD4":[38],"<":[39],"100":[40],"x":[41],"10(9)/liter":[42],"on":[43,52,103,156,228],"stable":[44],"antiretroviral":[45],"therapy.":[46],"Eighty-four":[47],"were":[49,195],"allocated":[50],"treatment":[51],"a":[53,106,123,140,153],"1:1":[54],"basis":[55],"to":[56,77,147,151,175],"or":[58,65],"placebo.":[59],"Patients":[60,102,118],"received":[61],"0.05":[63],"mg/m(2)":[64],"0.9%":[66],"saline":[67],"subcutaneously":[68],"three":[69],"times":[70],"weekly":[71],"for":[72,201],"48":[73,116],"weeks":[74],"(optional":[75],"extension":[76],"18":[78],"months).":[79],"primary":[81],"end":[82,94],"point":[83],"was":[84,172,198],"incidence":[86,158],"opportunist":[88,110],"infections":[89,111,212],"(CDC":[90],"categories":[91],"B/C).":[92],"Secondary":[93],"points":[95],"included":[96],"mortality,":[97],"immunological,":[98],"virological":[100],"parameters.":[101],"placebo":[104,179],"had":[105,122],"mean":[107,124],"3.45":[109],"(OIs)":[112],"first":[115],"weeks.":[117],"treated":[119],"1.71":[126],"OIs":[127],"(p":[128],"=":[129],"0.04).":[130],"However,":[131],"model":[133],"showed":[134],"overdispersion":[135],"inclusion":[138],"dispersion":[141],"factor":[142],"raised":[143],"p":[145],"value":[146],"0.13.":[148],"appeared":[150],"have":[152],"particular":[154],"effect":[155],"Candida,":[160],"herpes":[161],"simplex,":[162],"cytomegalovirus":[164],"infections.":[165],"Three-year":[166],"survival":[167,215],"arm":[171],"28%":[173],"compared":[174],"18%":[176],"group":[180],"(not":[181],"significant).":[182],"rIFN-gamma-associated":[183],"side-effects":[184],"headache,":[186],"fatigue,":[187],"rigors,":[188],"influenza-like":[189],"symptoms,":[190],"depression,":[191],"myalgia,":[192],"granulocytopenia":[194],"reversible.":[196],"There":[197],"no":[199],"evidence":[200],"HIV":[202],"activation.":[203],"Although":[204],"not":[205],"significant,":[206],"trend":[208],"towards":[209],"decreased":[210],"increased":[214],"warrants":[216],"consideration":[217],"further":[219],"trials":[220],"rIFN-gamma.":[222],"study":[224],"gives":[225],"additional":[226],"information":[227],"profile":[231],"this":[233],"cytokine.":[234]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}